Active Solicitation · DEPT OF DEFENSE
AI Summary
The Defense Advanced Research Projects Agency (DARPA) is seeking industry and academia input on capabilities for independent verification, validation, and commercialization support for hemorrhage countermeasures. This RFI aims to identify potential partners for assessing safety and efficacy, and to assist in transitioning products from research to market.
The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) seeks input from industry and academia regarding capabilities for providing independent verification and validation, clinical trial, and commercialization support for hemorrhage countermeasures. This Request for Information (RFI) is a preliminary step to identify potential partners capable of providing third-party assessments of safety and efficacy of potential hemorrhage countermeasures and assisting in development strategies to ensure said products transition from the laboratory to civilian and government markets after research, development, testing, and evaluation (RDT&E) efforts have ended. DARPA is particularly interested in respondents who can address all the above task domains to allow one provider to have comprehensive knowledge about the data for efficiency and to tailor commercialization and regulatory strategies.
Hemorrhage Countermeasure Evaluation Capabilities RFI is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.